In defining moment, spinout from Nobel Prize winner Jennifer Doudna's lab inks gene therapy deal

In defining moment, spinout from Nobel Prize winner Jennifer Doudna's lab inks gene therapy deal
·3 min read

The company, which emerged with a Covid-19 diagnostic, last month raised a $150 million Series D round.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting